跳至主要内容
临床试验/NCT07316439
NCT07316439进行中(未招募)不适用

Clinical Outcomes of ER-Positive to Negative Conversion Versus Triple-Negative Breast Cancer (TNBC): Evidence From a 18F-fluoroestradiol Positron Emission Tomography/Computed Tomography (18F-FES PET/CT) Guided Propensity-Score-Matched Study

Fudan University1 个研究点 分布在 1 个国家目标入组 197 人开始时间: 2024年12月31日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
197
试验地点
1
主要终点
Progression-Free Survival

研究概览

简要总结

This study aimed to compare survival outcomes and clinical characteristics between ER loss and metastatic triple-negative breast cancer (mTNBC) patients, exploring the prognostic implications of dynamic ER changes.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Patients diagnosed with breast cancer (according to International Classification of Diseases 10th Revision) with confirmed metastasis, regardless of being de novo diagnosed or progressed from a non-metastatic stage.
  • MBC patients who underwent 18F-FES PET/CT at the Fudan University Shanghai Cancer Center between 2017 and 2023
  • Patients diagnosed with primary ER-positive tumor and who were yet to receive any systemic therapy during the advanced stage
  • Contemporaneous patients with metastatic TNBC at initial diagnosis

排除标准

  • Patients with incomplete medical records and those diagnosed with secondary primary tumors

结局指标

主要结局

Progression-Free Survival

时间窗: 6 weeks

次要结局

  • Overall Response Rate(6 weeks)
  • Disease Control Rate(6 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Biyun Wang, MD

Professor

Fudan University

研究点 (1)

Loading locations...

相似试验